What happens to the sickest COVID patients? french ICU study aims to find out
NCT ID NCT04340466
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed over 1,000 adults with confirmed or suspected COVID-19 who were admitted to intensive care units (ICUs) across France. Researchers tracked their treatments, complications, and survival at 28 days. The goal was to learn how these patients are managed and what factors affect their outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand how to treat the sickest COVID-19 patients in intensive care and improve survival.
- What could go wrong
- This is an observational study, not a treatment trial, so it cannot prove what works best. Results may not apply to other countries or future variants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nimes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New tool aims to reduce physical restraints in ICUs
- Study aims to Fine-Tune antibiotic dosing for ICU patients
- Experimental drug aims to tame severe COVID-19 inflammation
- ICU suction procedure questioned: new study looks at lung effects
- Placenta cells tested as COVID fighter – but trial stopped early
- 5,000 ICU patients to help unlock secrets of critical illness